Efficacy and safety of alemtuzumab in 104 patients with active relapsing- remitting MS: one-year follow-up in France
X. Ayrignac,N. Collongues,J. De Seze,P. Vermersch,D. Biotti,D. Brassat,C. Carra-Dalliere,S. Vukusic,F. Durand-Dubief,G. Edan,E. Lepage,V. Deburghgraeve,E. Maillart,C. Papeix,P. Alla,E. Berger,B. Bourre,O. Casez,S. Pittion,M. Debouverie,M. Theaudin,N. Derache,G. Defer,O. Gout,R. Deschamps,A. Tourbah,F. Zagnoli,A. Ruet,J. C. Ouallet,B. Brochet,E. Manchon,T. Moreau,A. Fromont,P. Clavelou,F. Taithe,A. M. Guennoc,J. P. Camdessanche,A. Carpentier, I. Coman,B. Audoin,J. Pelletier,A. Rico,L. Magy,J. Ciron,S. Wiertlewski,D. Laplaud,T. De Broucker,C. Lebrun,M. Cohen,P. Labauge MULTIPLE SCLEROSIS JOURNAL(2016)
AI 理解论文
溯源树
样例